Merck & Co. Inc. (MRK)

72.40
0.19 0.26
NYSE : Health Technology
Prev Close 72.21
Open 72.31
Day Low/High 71.94 / 72.66
52 Wk Low/High 52.83 / 72.89
Volume 1.84M
Avg Volume 8.14M
Exchange NYSE
Shares Outstanding 2.66B
Market Cap 191.01B
EPS 0.90
P/E Ratio 143.64
Div & Yield 1.92 (2.70%)
Small Cap Biotech Bargains

Small Cap Biotech Bargains

Here are 2 small caps I continue to see as bargains in this space.

Sanofi, Merck and J&J Tout Lower Drug Prices

Sanofi, Merck and J&J Tout Lower Drug Prices

While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.

Jim Cramer: Tech Can't Do it All Alone

Jim Cramer: Tech Can't Do it All Alone

Tech and retail gains aren't enough to lead markets to new highs.

IQiyi, the Netflix of China, Marches Higher; Apple's WWDC, Fiat and More--ICYMI

IQiyi, the Netflix of China, Marches Higher; Apple's WWDC, Fiat and More--ICYMI

Here's what you need to know for Monday, June 4.

LYNPARZA® (olaparib) In Combination With Abiraterone Delayed Disease Progression In Metastatic Castration-Resistant Prostate Cancer

LYNPARZA® (olaparib) In Combination With Abiraterone Delayed Disease Progression In Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data which showed clinical improvement in median radiologic progression-free survival (rPFS) with LYNPARZA ® (olaparib) in combination with abiraterone...

Dow Gains 178 Points; Nasdaq Jumps to New Record

Dow Gains 178 Points; Nasdaq Jumps to New Record

Stocks rise on Monday as stronger-than-expected jobs data from the U.S. overshadows trade fears.

Merck Higher on Lung Cancer Data

Merck Higher on Lung Cancer Data

The drugmaker's presentations at ASCO's annual meeting included data on Keynote-407, which Credit Suisse analyst Vamil Divan described as a 'clear positive.'

Two Year Update Of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses With BAVENCIO® (avelumab)

Two Year Update Of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses With BAVENCIO® (avelumab)

/NOT INTENDED FOR US, CANADA AND UK-BASED MEDIA./  Two-year follow-up d ata on meaningful durable response , overall survival (OS) and progression-free survival (PFS) to be presented in patients with metastatic Merkel cell carcinoma (mMCC), a rare and...

Merck KGaA, Darmstadt, Germany Presents Updated Clinical Results For Bifunctional Immunotherapy M7824 At ASCO 2018

Merck KGaA, Darmstadt, Germany Presents Updated Clinical Results For Bifunctional Immunotherapy M7824 At ASCO 2018

DARMSTADT, Germany, June 4, 2018 /PRNewswire/ -- ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584 ; M6620 (ATR inhibitor): 2549; M3814...

Two-Year Update Of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses With BAVENCIO® (avelumab)

Two-Year Update Of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses With BAVENCIO® (avelumab)

CHICAGO, June 4, 2018 /PRNewswire/ -- Not intended for UK-based media   Two- year follow-up data on meaningful durable responses , overall survival (OS) and progression-free survival (PFS) to be presented in patients with metastatic Merkel cell carcinoma...

Merck's KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity In Patients With Advanced Small Cell Lung Cancer (SCLC) In Phase 2 KEYNOTE-158 Study

Merck's KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity In Patients With Advanced Small Cell Lung Cancer (SCLC) In Phase 2 KEYNOTE-158 Study

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced interim data from a cohort of the Phase 2 KEYNOTE-158 study evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy in patients with previously treated advanced...

Merck's KEYTRUDA® (pembrolizumab) Demonstrated Long-Term Survival Benefit Based On Four And Five Years Of Follow-Up From Two Pivotal Studies In Advanced Melanoma

Merck's KEYTRUDA® (pembrolizumab) Demonstrated Long-Term Survival Benefit Based On Four And Five Years Of Follow-Up From Two Pivotal Studies In Advanced Melanoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced long-term efficacy data from the Phase 3 KEYNOTE-006 study and the melanoma cohort of the Phase 1b KEYNOTE-001 study investigating KEYTRUDA, Merck's anti-PD-1 therapy, in...

Eisai And Merck Announce Data At 2018 ASCO Annual Meeting From Investigational Studies Of LENVIMA® (lenvatinib) And KEYTRUDA® (pembrolizumab) Combination Therapy In Four Different Tumor Types

Eisai And Merck Announce Data At 2018 ASCO Annual Meeting From Investigational Studies Of LENVIMA® (lenvatinib) And KEYTRUDA® (pembrolizumab) Combination Therapy In Four Different Tumor Types

-- First presentation of LENVIMA/KEYTRUDA data in patients with unresectable hepatocellular carcinoma (HCC), which aims to be the first systemic combination of a TKI and immunotherapy for these patients, as well as squamous cell carcinoma of the head and neck (SCCHN)

Merck's KEYTRUDA® (pembrolizumab) Showed Overall Response Rate Of Nearly 40 Percent As First-Line Therapy In Patients With Advanced Clear Cell Renal Cell Carcinoma (RCC) In Phase 2 KEYNOTE-427 Study

Merck's KEYTRUDA® (pembrolizumab) Showed Overall Response Rate Of Nearly 40 Percent As First-Line Therapy In Patients With Advanced Clear Cell Renal Cell Carcinoma (RCC) In Phase 2 KEYNOTE-427 Study

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell...

Merck KGaA, Darmstadt, Germany Presents Update On Tepotinib In Advanced Lung Cancer At ASCO 2018

Merck KGaA, Darmstadt, Germany Presents Update On Tepotinib In Advanced Lung Cancer At ASCO 2018

DARMSTADT, Germany, June 3, 2018 /PRNewswire/ -- Not intended for UK-based media   ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR...

Merck Presents Update On Tepotinib In Advanced Lung Cancer At ASCO 2018

Merck Presents Update On Tepotinib In Advanced Lung Cancer At ASCO 2018

/NOT INTENDED FOR UK- OR US-BASED MEDIA/ DARMSTADT, Germany, June 3, 2018 /CNW/ - ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR...

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival In First-Line Treatment Of Metastatic Squamous Non-Small Cell Lung Cancer In Phase 3 KEYNOTE-407 Study

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival In First-Line Treatment Of Metastatic Squamous Non-Small Cell Lung Cancer In Phase 3 KEYNOTE-407 Study

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from KEYNOTE-407, a pivotal, Phase 3 study evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel, as...

Income Seeker: Verizon's 5% Yield Is No Mere Dog of the Dow

The telecom giant is the highest-yielding stock among the Dow industrials.

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival And Progression-Free Survival As First-Line Treatment For Squamous Non-Small Cell Lung Cancer (NSCLC) In Pivotal Phase 3 KEYNOTE-407 Trial

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival And Progression-Free Survival As First-Line Treatment For Squamous Non-Small Cell Lung Cancer (NSCLC) In Pivotal Phase 3 KEYNOTE-407 Trial

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-407 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel, as first-line...

Merck Announces Third-Quarter 2018 Dividend

Merck Announces Third-Quarter 2018 Dividend

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

These names are moving up or down in a big way ahead of releasing drug-trial results.

New Data From Merck's Leading Immuno-Oncology Clinical Development Program In Over 25 Tumor Types To Be Presented At 2018 ASCO Annual Meeting

New Data From Merck's Leading Immuno-Oncology Clinical Development Program In Over 25 Tumor Types To Be Presented At 2018 ASCO Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from Merck's oncology portfolio, anchored by anti-PD-1 therapy KEYTRUDA, will be presented at the 54 th Annual Meeting of...

4 Names to Buy in a Refreshed Biotech Space

4 Names to Buy in a Refreshed Biotech Space

After a strong week for the biotech sector, these names have potential catalysts to move shares.

Healthcare Stocks Rebound After President Trump's Speech on Drug Pricing

Healthcare Stocks Rebound After President Trump's Speech on Drug Pricing

President Trump delivered a highly-anticipated speech on lowering the cost of drugs for Americans on Friday afternoon.

LYNPARZA® (olaparib) Tablets Receive EU Approval For The Treatment Of Platinum-Sensitive Relapsed Ovarian Cancer

LYNPARZA® (olaparib) Tablets Receive EU Approval For The Treatment Of Platinum-Sensitive Relapsed Ovarian Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency (EMA) has approved LYNPARZA ® (olaparib) tablets (300 mg twice daily) for use as a maintenance therapy for patients...

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.

TheStreet Quant Rating: B+ (Buy)